BioSpace News Archive

Helping Health Professionals Combat The Vaccine Hesitancy Crisis

Santhera Pharmaceuticals reports first half-year results as of June 30, 2019, and provides an update on its pipeline and strategic focus.

Achilles Therapeutics announces it has closed a £100 million Series B financing led by incoming U.S. investor RA Capital Management, corner-stoned by founding investor Syncona and joined by important new investors including Forbion, Invus, Perceptive Advisors and Redmile Group.

Financing will support continued clinical development of gene therapies and surgical delivery systems for retinal diseases

Akari Therapeutics, Plc announced that Clive Richardson, Chief Executive Officer, will participate and host investor meetings at the following September Conferences:

The capability to combine more materials, cells and tools has the potential to enhance research applications across the bioprinting field. To support users worldwide, CELLINK developed the BIO X6.

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation and Rare Pediatric Disease Designation to GTX-102 for the treatment of Angelman Syndrome, a serious, debilitating rare neurogenetic disorder that affects approximately 1 in 15,000 people worldwide.

4TEEN4 Pharmaceuticals GmbH demonstrates that targeting the enzyme Dipeptidyl Peptidase 3 with its first-in-class therapeutic antibodyProcizumab normalises heart and kidney function ina preclinical models of acute heart failure with depressed contraction.

HOOKIPA Pharma Inc. announced that HOOKIPA’s management team will present and host one-on-one meetings at the following investor conferences in September

Forbion announces that it has participated in a £100 million Series B financing of Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies.